

#6B

Cretostimogene Induces Acute Th1 Skewed Inflammation in BCG-Unresponsive CIS-Containing Non-Muscle Invasive Bladder Cancer (BOND-003 Cohort C)

Colin P. N. Dinney, MD^{1*}; David McConkey, PhD¹; Trinity J. Bivalacqua, MD, PhD²; Gary D. Steinberg, MD³; Sarah Donatelli, PhD⁴; Mark Tyson, MD, MPH⁵

¹Department of Urology, University of Rochester Medical Center, Rochester, New York; ²Department of Urology, University of Pennsylvania, Philadelphia, Pennsylvania;

³Department of Urology, Rush University Medical Center, Chicago, Illinois; ⁴CG Oncology, Dallas, Texas; ⁵Department of Urology, Mayo Clinic, Phoenix, Arizona



For individual reference only. The information accessed through this QR code is intended solely for individual reference and should not be altered, modified, or reproduced in any way.

BACKGROUND

- Cretostimogene grenadenorepvec is an oncolytic immunotherapy that lyses Rb-E2F–altered tumor cells and amplifies anti-tumor immunity via a GM-CSF transgene
- BOND-003 Cohort C is a Phase 3 study in patients with CIS–containing, BCG-unresponsive NMIBC¹
- As of 23 June 2025:
 - CR rate at any time was 75.5%
 - Median DOR: 27.9 months and ongoing
- Urinary cytokines (a surrogate of local immune milieu) were profiled post-treatment to characterize the immune-mediated MOA

METHODS

- Serial urine collected pre-dose (–2 hr) and post-dose (+2 hr) across treatment phases from BOND-003 Cohort C biomarker consented participants (n=60)
- Tested with Olink Target 48 Cytokine panel
- Results of Week 1-6 (induction phase) are displayed as raw NPX (log₂-scaled) or ΔNPX (log₂ fold-change) vs. within-subject baseline (W1).

Figure 1. BOND-003 Cohort C: Urine Collection Relative to Cretostimogene Dosing.

HR BCG-Unresponsive NMIBC CIS ± HG Ta/T1				Cretostimogene Grenadenorepvec Oncolytic immunotherapy Dual MOA						Primary Endpoint CR at Any Time				
Study Phase →		Screen	Induction (Weekly × 6)						M3	Maintenance			Extended Maintenance	
Study Week / Visit	SCR	1	1 D4	2	3	4	5	6	13-15	25-27	37-39	49-51	73-75	99-159
Cretostimogene instillation			no dose (predose)											
Urine collection														

Cretostimogene dose (×N doses per cycle)


Urine (Olink) collection

W1D4* = peak viral replication (C_{max}); predose only

Abbreviations: BCG: Bacillus Calmette-Guerin; CIS: carcinoma in situ; CR: complete response; GM-CSF: granulocyte-macrophage colony-stimulating factor; MOA: mechanism of action; NMIBC: non-muscle invasive bladder cancer; NPX: normalized protein expression; Th1: T helper type 1 **References:** 1 Tyson et al., Lancet Oncology, 2026.


RESULTS

Figure 2. Cretostimogene drives coordinated, multi-lineage inflammatory cytokine induction




Median ΔNPX (log₂ fold-change vs. W1 Pre) across 45 urinary analytes at post-dose induction timepoints (W1 +2h–W6 +2h), grouped by functional module. Red indicates induction, blue suppression, white no change; rows are grouped by functional module. Coordinated induction of Th1, Th17, M1, DC-priming, and TNF-superfamily analytes is evident at post-dose timepoints. Most groups peaked early (W1D4–W2 post-dose); Th17 cytokines peaked later (~Week 6). Th2 and immunoregulatory cytokines remained largely below the limit of detection and were not induced.

Figure 3. Robust GM-CSF expression associated with M1/Th1/Th17-dominant local response




Maximum ΔNPX (log₂ fold-change vs. baseline) per analyte during induction (W1–6), for analytes increasing ΔNPX > 2 over baseline, colored by functional group. GM-CSF (CSF2) shows the largest induction (~300-fold peak at W1 D4).

Figure 4. Cretostimogene shifts NMIBC myeloid compartment from immunosuppressive (M2) to inflammatory (M1) phenotype during induction.



Analyses use per-subject ΔNPX (log₂ fold-change from each subject's Week 1 pre-dose baseline), computed per analyte. Box plots show median and IQR (Tukey whiskers) with subjects overlaid; the dotted line marks baseline (ΔNPX = 0), above which reflects a shift toward M1. (a) M1 module (CSF2, CCL3, CCL4, CCL7) versus M2/TAM module (CCL8, OSM, MMP1, MMP12, CSF1, CCL2, OLR1) induction (per-subject median ΔNPX); M1 significantly exceeds M2 at every post-dose timepoint. (b) Combined M1:M2 ratio (M1 – M2 median ΔNPX), which increases significantly from baseline. Data were analyzed by a mixed-effects model (REML) with subject as a random effect: (a) two-way (module × time) with Šidák's correction; (b) Dunnett's test versus baseline. ****p<0.0001.

Figure 5. Cretostimogene induces acute, transient, multi-lineage inflammatory cytokine responses that resolve between instillations



Longitudinal urinary NPX (median ± IQR) for representative induced analytes across paired pre/post-dose timepoints (W1–W6). Representative analytes span M1/inflammatory-macrophage (CSF2, CCL3, CCL4), Th1/IFN-γ-axis (CXCL9, CXCL10, CXCL11, IFN-γ), DC-priming (CCL19), Th17/neutrophil (IL-17A), and M2/TAM (CCL8, OSM, MMP1) modules. Values are raw NPX (log₂-scaled); dotted lines denote the least- and most-conservative plate-specific LODs. Post-dose induction with return toward baseline before subsequent dosing indicates repeated acute, self-limiting immune activation.

CONCLUSION

- Cretostimogene induces a transient, potentially GM-CSF–driven acute inflammatory program—Th1/IFN-γ, Th17 inflammation, DC priming (CCL19), cytotoxic/apoptotic signaling (TRAIL), and M1 myeloid polarization—without Th2, regulatory cytokine induction, resolving between doses with preserved bladder homeostasis.
- These data provide mechanistic support for cretostimogene's MOA—productive, immunogenic anti-tumor inflammation—consistent with the high, durable CR rates in BOND-003 Cohort C.

Contact Information: Colin P.N. Dinney: Colin.Dinney@cgoncology.com

Acknowledgements: Pat Keegan, MD; Rob Svatek, MD; Shelja Patel, PharmD; Sarah D. Hohl, PhD; and Vijay Kasturi, MD